Develop therapeutics for genetically driven muscle diseases. Utilize the FORCE platform to deliver disease-modifying treatments. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.
Clearly below the class average.
Clearly below the class average.
The price is looking for direction — no strong breakout, no collapse.
Growth: Sales growth trails the sector average.
Business Quality: Profit power and business quality trail similar companies in the sector.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Executive Buying: The trades send no strong signal of confidence.
An investor who bought at the very peak is down 61% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Our checks did not surface a specific strength to highlight here.
A loss of $446.2M against $0 in annual sales.
At the current pace of spending, the cash lasts about 2.5 years. After that, the company needs to find new money.
Over the last 12 months, executives reported 123 sells against just 25 buys. Not an alarm bell by itself, but a number worth watching.
On our five-subject report card, DYN sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: DYN is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (39/100) says the stock isn’t cheap.
Not covered, because the filings we hold do not carry it: the revenue breakdown.